Keyphrases
Tumor
100%
Gene Therapy
100%
Interleukin-6
100%
Interleukin-6 Inhibitors
100%
Receptor Antagonist
81%
Tocilizumab
27%
IL-6 Level
18%
Gene Delivery
18%
Clinical Conditions
9%
Virus
9%
Cell Growth
9%
Adenovirus
9%
Monoclonal Antibody
9%
Biological Activity
9%
Malignancy
9%
Genetic Engineering
9%
IL-6 Gene
9%
Humanized
9%
Gene Delivery System
9%
Human Immunoglobulin
9%
Vector Encoding
9%
Adenovirus Vector
9%
Interleukin-6 Receptor (IL-6R)
9%
Inflammatory Diseases
9%
Myeloma Cells
9%
Interleukin-6 Signaling
9%
Therapeutic Gene
9%
Binding Activity
9%
Immunoglobulin G1
9%
Chain Fragments
9%
Level Reduction
9%
Gene Introduction
9%
Anti-interleukin-6
9%
Anti-interleukin-6 Receptor
9%
Delivery Approaches
9%
Reduction Property
9%
Fc Portion
9%
Growth Reduction
9%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Interleukin 6
100%
Interleukin 6 Receptor
100%
Receptor
56%
Tocilizumab
18%
Gene Delivery
12%
Diseases
12%
Multiple Myeloma
6%
Biological Activity
6%
Adenoviridae
6%
Monoclonal Antibody
6%
Adenovirus Vector
6%
Gene Delivery
6%
Inflammatory Disease
6%
Immunoglobulin G1
6%
Human Immunoglobulin
6%
Immunology and Microbiology
Interleukin 6
100%
Interleukin-6 Receptor
100%
Tocilizumab
18%
Gene Targeting
12%
Monoclonal Antibody
6%
Cell Growth
6%
Inflammatory Disorder
6%
Adenovirus Vector
6%
Adenoviridae
6%
Binding Affinity
6%
Human Immunoglobulin
6%
Immunoglobulin G1
6%
Gene Delivery System
6%
Multiple Myeloma Cell Line
6%
Virus
6%
Biological Activity
6%